General Information of This Antibody
Antibody ID
ANI0UTUMU
Antibody Name
Magacizumab
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG4-kappa
Antigen Name
Leucine-rich alpha-2-glycoprotein (LRG1)
 Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
LRG1-ADC 5 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 52.40% (Day 16) Positive LRG1 expression (LRG1+++/++)
Method Description
Single-cell suspensions of 1 x106 B16F0 cells were injected subcutaneously into the lower back of Lrg1+/+ C57BL/6 mice in 100 mL PBS. Tumours were measured and therapy was initiated when tumour volumes reached 0.1 cm3. ADC was administered at a dose of 20 mg/kg treatments were administered by a single intraperitoneal injection every 7 days for 3 weeks.

   Click to Show/Hide
In Vivo Model Melanoma CDX model
In Vitro Model Melanoma Melanoma cells Homo sapiens
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.90 nM
Positive LRG1 expression (LRG1+++/++)
Method Description
5 x104 cells were seeded in 96-well plates and incubated at 37 overnight. Cells were thenexposed to a range of concentrations of the test compounds diluted in growth medium at pH 6.5 and at 37 as ADC 5 (0100 nM, 72 h). MTT reagent (12 mM) was then added to each well and cells were incubated for 4 h at 37 , followed by the addition of DMSO and further incubation at 37 1C for 1 h.

   Click to Show/Hide
In Vitro Model Mouse melanoma B16-F0 cells CVCL_0604
References
Ref 1 Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chem Biol. 2021 May 31;2(4):1206-1220.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.